Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1111/j.1365-2141.2011.08653.x

Abstract

No abstract available.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Drummond, Dr Mark and Holyoake, Professor Tessa and Gallipoli, Dr Paolo and Irvine, Dr David
Authors: Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M., and Holyoake, T.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:British Journal of Haematology
Journal Abbr.:Brit. J. Haematol.
Publisher:Blackwell
ISSN:0007-1048
ISSN (Online):1365-2141
Published Online:22 April 2011
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
540351The relevance of autocrine growth factor activation to the survival and proliferation of primitive chronic myeloid leukaemia (CML) cells.Paolo GallipoliMedical Research Council (MRC)G1000288Institute of Cancer Sciences